Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Makes Case For Frontline Use Of Myeloma Drug Sarclisa

Promising Data In Newly Diagnosed Transplant-Eligible Patients

Executive Summary

Sarclisa, Sanofi's first in-house cancer drug to be approved since 2010, is making slow if steady progress on the sales front but remains way behind J&J's multiple myeloma behemoth Darzalex. Still, the company has been touting its case to be the anti-CD38 of choice at the ASH meeting.

You may also be interested in...



Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow

The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.

Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa

The French major has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.

Ichnos Gets Going With Almirall Deal, Multiple Myeloma Bispecifics Add Sheen

Glenmark’s US-based innovation arm Ichnos delivers first licensing deal for IL-1RAP antagonist, while early data for a bispecific antibody demonstates promising activity in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel